pharmacokinetic investigations after oral and intravenous application of 50 mg and 100 mg 7-chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1h-1,4-benzodiazepine-3-carbonic acid ( dipotassium clorazepate , dpc , tranxilium , tranxene ) were conducted with two groups of male subjects ( a : n = 7 ;
C0009033
dipotassium clorazepate
C0699937
tranxene